Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UCB | Brussels | Healthcare | Pharmaceuticals | €27.76B | 26x | 0.13 | €146.15 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.9% Upside | Upgrade to Pro+ | |
Tubize-Fin | Brussels | Healthcare | Pharmaceuticals | €5.10B | 56.7x | 26 | €114.40 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fagron | Brussels | Healthcare | Pharmaceuticals | €1.35B | 16.9x | 1.23 | €18.60 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.1% Upside | Upgrade to Pro+ | |
Hyloris | Brussels | Healthcare | Pharmaceuticals | €140M | -13.4x | €6.01 | 20.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Biosenic | Brussels | Healthcare | Pharmaceuticals | €1.21M | -0.1x | -0 | €0.002 | 10% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |